This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of any platinum infusion duration to prevent hearing loss and/or tinnitus in children with cancer treated with platinum-based therapy (i.e. including cisplatin, carboplatin and/or oxaliplatin) when compared to another infusion duration. We will also assess possible effects of these infusion durations on anti-tumour efficacy (i.e. tumour response and survival) of platinum-based therapy, on adverse effects other than hearing loss and/or tinnitus and on quality of life.